Abstract
Background: Breast cancer is the most prevalent site-specific cancer and one of the most frequent causes of cancer death in women worldwide. Neoadjuvant chemotherapy, along with surgical treatment—breast conserving surgery (BCS) or mastectomy—is an important part of treatment for locally advanced breast cancer. As BCS is preferred to mastectomy in terms of cosmetic, quality-of-life, and functional outcomes, it would be the preferred treatment for locally advanced breast cancer (LABC), if its oncological safety is confirmed.Methods: In this study, we retrospectively compared the oncologic outcomes of post-neoadjuvant chemotherapy BCS with mastectomy in 202 patients with LABC. Results: There were no significant differences between BCS and mastectomy regarding overall survival, local recurrence, contralateral breast cancer, and distant metastasis.Conclusions: Our study showed that post-neoadjuvant chemotherapy BCS is an oncologically safe surgical treatment in LABC and that BCS can be considered as an acceptable treatment in selected patients with LABC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
